Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension of the Halt Cardiomyopathy Progression in Duchenne (HOPE-Duchenne) Trial (CAP-1002-DMD-03)

NCT06304064 is registered in ClinicalTrials.gov with Capricor Inc. as lead sponsor.

NCT NCT06304064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06304064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension of the Halt Cardiomyopathy Progression in Duchenne (HOPE-Duchenne) Trial (CAP-1002-DMD-03)
Lead sponsor
Capricor Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 21, 2018
Completion date
March 6, 2019
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy